News|Articles|November 18, 2024
Elevating and De-Risking Your Drug Portfolio Strategy With AI
Author(s)Intelligencia AI
Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs
2
Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff
3
Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics
4
Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics
5